Background: Potent P2Y 12 inhibitors may offer enhanced benefit against thrombotic events in complex percutaneous coronary intervention (PCI). We examined prasugrel use and outcomes by PCI complexity, as well as analyzing treatment effects by thienopyridine type.
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INTRODUCTION
Percutaneous coronary intervention (PCI) in complex lesion subsets is associated with high thrombotic risk and greater susceptibility for both stent related and non-related short and long-term adverse events [1] [2] [3] . There is no universal definition for complex PCI and different classifications using combinations of lesion and procedural characteristics account for 10%-50% of all PCI patients in current clinical practice [2] [3] [4] . In particular, PCI of the left main, bifurcation target lesion, moderate or severely calcified lesion or stent implantation of ≥30mm are procedural parameters correlated with greater event rates in prior studies [5] [6] [7] [8] . Other authors have also attributed complex PCI status to chronic total occlusion (CTO) PCI, saphenous vein graft (SVG) PCI, use of rotablation atherectomy, target lesion with thrombus, tortuous target vessel, ultralong stent length >60mm, or factors based on total number of lesions treated or stents implanted [3, 4, [9] [10] [11] . Notwithstanding these anatomical variances in definition, risk may be further compounded in the setting of acute coronary syndromes (ACS) [12] . There are currently no outcomes data by PCI complexity in large ACS cohorts treated with contemporary PCI technologies. Furthermore, whether use of potent antiplatelet therapies provides preferential benefit to mitigate risk of recurrent thrombotic events following PCI in such high-risk patients has not been investigated.
Potent P2Y 12 therapies such as prasugrel and ticagrelor result in rapid, uniform and more potent platelet inhibition than clopidogrel with significantly reduced risk of 1-year ischemic outcomes [13, 14] . These agents are also recommended in guidelines for treatment of ACS patients undergoing PCI [15, 16] . However, the potential role of these potent agents has not been systematically examined by PCI complexity in randomized trials, thus specific recommendations by anatomical risk are presently lacking. Moreover, the decision for selection of potent inhibitors following complex PCI may be outweighed by concomitant risk of bleeding, thus negating the net benefit of such therapies [13, 14, 17] .
We conducted a post-hoc analysis from a multicenter observational study of 19,914 patients undergoing ACS PCI in 8 academic US centers 1) to analyze 1-year outcomes by PCI complexity,
and 2) to examine the patterns of prasugrel use and to assess 1-year outcomes by thienopyridine type and PCI complexity.
METHODS
Study sample
The PROMETHEUS study was a multicenter observational study including patients undergoing PCI between 1 January 2010 to 30 June 2013 at 8 academic US centers that maintained a prospective PCI database with 1-year follow-up [18] . The institutional ethics committees of all centers approved the study. All data were prospectively collected and then retrospectively extracted and harmonized for analysis. The data fields extracted followed standardized definitions of the National Cardiovascular Data Registry (NCDR) Catheterization PCI database and were jointly agreed to by the study investigators. The main study was designed to compare use of prasugrel and clopidogrel in all-comer ACS PCI. Management of data quality, statistical analyses and results reporting were the responsibility of the Data Coordinating Center at the Icahn School of Medicine at Mount Sinai, New York. The sponsors did not have access to patient-level data.
The study population included all patients undergoing PCI for ACS and treated with dual antiplatelet therapy (DAPT) with aspirin and either clopidogrel or prasugrel. The current analysis was stratified by the PCI complexity as complex vs. non-complex using the study definition ( Figure   1 ). The PCI procedure and related management was carried out per usual standard of care and at the discretion of the treating physicians at each site. Prescription of prasugrel or clopidogrel in individual patients was also directed by the treating physician.
Endpoints and Definitions
Complex PCI was defined as PCI with any 1 of the following characteristics: left main PCI location, bifurcation target lesion treated with any technique, moderate or severely target calcified target lesion or total implanted stent length ≥30mm. This definition was agreed on by the study authors based on prior studies indicating higher risk in these patient subsets [5] [6] [7] [8] We also examined the frequency of prasugrel use, prevalence of high-risk baseline features and the incidence of MACE and clinically significant bleeding in the overall population by number of complex features (0 to ≥3 for none, left main PCI, bifurcation PCI, moderate or severely calcified lesion, ≥30mm stent length).
STATISTICAL ANALYSIS
Patients were grouped and compared by PCI complexity. Categorical data are presented as numbers and percentages and compared using the chi-square test. Continuous data are presented as means and standard deviations and compared using the parametric Student's t test. Clinical event rates are presented using the Kaplan Meier method and compared using the log rank test.
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A C C E P T E D ACCEPTED MANUSCRIPT 8 Hazard ratios and confidence intervals for adjusted risk of 90-day and 1-year outcomes between patients with complex vs. non-complex PCI were generated using multivariable Cox regression methods (reference =non-complex PCI), adjusting for the following variables: age, African-American or other race, body mass index (BMI), diabetes, hypertension, estimated glomerular filtration rate, hemoglobin, prior PCI, coronary artery disease (CAD) presentation, multivessel disease, bivalirudin use, stent type, prasugrel use and center. Similarly adjusted hazard ratios and confidence intervals for MACE associated with each component of complex PCI were generated using multivariable Cox regression methods accounting for the following variables: age, African-American or other race, body mass index (BMI), diabetes, hypertension, estimated glomerular filtration rate, hemoglobin, prior PCI, coronary artery disease (CAD) presentation, bivalirudin use, stent type, prasugrel use and center.
Further, adjusted hazard ratios and confidence intervals for risk of 90-day and 1-year outcomes with prasugrel vs. clopidogrel (reference = clopidogrel) among complex and non-complex PCI patients were generated using Cox proportional hazards regression stratified by propensity to receive prasugrel, with formal interaction testing between P2Y 12 inhibitor treatment and PCI complexity. The propensity model included the following main effects: center, CAD presentation, diabetes, age, age squared, bivalirudin, smoking, gender, African-American race, hypertension, family history of CAD, prior PCI, prior coronary artery bypass surgery (CABG), prior peripheral arterial disease, prior congestive heart failure, prior cerebrovascular disease (CVD), stent length, stent diameter, glycoprotein IIb/IIIa inhibitor use, hypercholesterolemia, prior myocardial infarction, estimated glomerular filtration rate, stent type, body mass index (BMI), hemoglobin and the following interaction terms: center*procedural glycoprotein IIb/IIIa inhibitor use; BMI*hemoglobin; prior CVD*prior PCI; prior CVD*prior CABG.
All data were analyzed using Stata version 14.0 (College station, Texas) or SAS version 9.4 (Cary, NC); p-values < 0.05 were considered significant.
RESULTS
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A C C E P T E D ACCEPTED MANUSCRIPT 9 A total of 19,914 patients were included in the study, of whom 48.9% (n=9,735) underwent complex PCI and 51.1% (n=10,179) underwent non-complex PCI per the study definition. Tables 1 and 2 show the baseline and procedural characteristics by PCI complexity. Complex PCI patients were older than non-complex PCI patients with a higher prevalence of diabetes, multi-distribution vasculopathy and multivessel disease. In the complex group, left main PCI was performed in 6.9%, bifurcation PCI in 20.1% and moderate or severe target lesion calcification was present in 28.9%.
The mean stent length was 42.9mm in complex vs. 18.9mm in non-complex patients (p < 0.0001).
Second generation drug eluting stents (DES) were used more often in complex PCI patients (70.1% vs. 66.2%, p <0.001). Complex PCI patients were more likely to be treated with glycoprotein IIb/IIIa inhibitors (24.0% vs. 21.9%, p =0.0002). Prasugrel was used in 20.7% of complex and 20.1% of non-complex PCI patients (p=0.30). The frequency of prasugrel by CAD presentation is shown in 
Risks associated with complex PCI
Complex PCI has been the subject of many recent reports [3, 4, [9] [10] [11] and although a universal definition is lacking several descriptions have been used, including some of the characteristics we utilized in our study definition, which have been shown to be associated with long-term adverse events in prior studies [4] [5] [6] [7] [8] [9] . The left main subtends 100% of the left ventricular myocardial territory in a left dominant circulation and 70% in right dominant circulation [19] . While we did not have precise information on protected vs. unprotected left main lesions, nearly half of the left main lesions (n=301) were noted in patients without prior history of CABG. Majority of left main PCI involves the distal bifurcation, which is associated with the highest risk [5, 20, 21] . Indeed, bifurcation lesions remain associated with high rates of target lesion failure, even though use of 2 nd generation DES has been observed to be protective [22] . Further, bifurcation lesions treated with a simple or complex strategy may be associated with greater risk than a non-bifurcation lesion due to procedure M A N U S C R I P T
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12 related plaque shift, alteration of flow and risk of poor stent apposition [23] . Calcified lesions increase procedural technical difficulty requiring adjunctive use of intravascular imaging, rotablation atherectomy, guideliner support and higher inflation pressures to achieve stent optimization [24] .
Further, several studies have shown that stent length >30mm is linked with greater risk for MACE, ST and target vessel revascularization [3, 7, 25] . Total stent length also serves as a surrogate for number of lesions and vessels treated and number of stents implanted. Although studies have also shown that number of vessels treated and number of stents implanted are associated with greater risk [4, 26] , we were limited by missingness of information for number of stents. Furthermore multivessel PCI and number of stents were strongly associated with stent length ≥30mm, therefore we used the latter as a proxy variable.
Indeed, we observed each component of our definition of complex PCI to be associated with higher adjusted risk of MACE both at 90-days and 1-year. However, other experts contend that lesion complexity should be considered in conjunction with systemic comorbidities, to allow comprehensive assessment of predicted risk [2] . Certainly patients undergoing complex PCI in the current study were more likely to have greater atherothrombotic risk factors including diabetes, prior MI and history of smoking, but they presented more frequently with unstable angina rather than troponin positive ACS.
Both at 90-days and 1-year, complex PCI correlated with greater adjusted risk for MACE driven by death, MI and unplanned revascularization. Despite predominant 2 nd generation DES use, complex patients were at significantly higher risk of MI and ST, thus PCI complexity was independently associated with both stent related and non-stent related thrombotic outcomes following PCI. Other studies have noted similar findings of greater adverse event rates attributed to PCI complexity [3, 4, 9] . However, mortality reductions exceeding reductions in MI observed in our study strongly suggest that residual confounding from unmeasured parameters may account for greater mortality in complex PCI patients. Although we observed a borderline trend for greater adjusted risk of bleeding in complex patients, this was not statistically significant. The recent complex PCI patient-level pooled analysis from 6 randomized controlled trials also did not M A N U S C R I P T
13 demonstrate greater hazard for bleeding in complex PCI, however the eligibility criteria of the included trials may have precluded enrollment of patients at highest risk of bleeding [4] .
Selecting patients for prasugrel
Despite higher adjusted risk of MACE in complex PCI patients, use of prasugrel was notably similar in both groups. However, when examined by the number of complex PCI features, prasugrel use declined with rising PCI complexity. Conversely a stepwise increase was noted in the incidence of both MACE and bleeding from 0 to ≥3 complex features. Additionally, we observed that with advancing PCI complexity, the frequency of risk factors for bleeding where prasugrel use is generally not recommended per the Food and Drug administration label [27] , specifically, age ≥ 75 years, weight <60kg and history of prior cerebrovascular disease, gradually increased, providing a plausible explanation for the decrease in prescription rates. Moreover, other risk factors associated with bleeding such as prevalence of chronic kidney disease (CKD) and pre-existing anemia were higher in increasingly complex patients [28, 29] . In fact, these bleeding risks may not only influence prescription rates, but also adherence to antiplatelet therapy [30, 31] . Our study suggests that prasugrel, while prescribed more frequently in patients with one complex PCI characteristic, was less often used in the setting of multiple complex PCI features. Ongoing studies will examine whether a novel strategy of aspirin withdrawal and continued potent antiplatelet monotherapy yields benefit in complex PCI patients [32, 33] . Alternatively whether switching down from potent P2Y 12 therapy to clopidogrel after the first month is beneficial in high bleeding risk complex PCI patients is not known [34] . Importantly, the recent complex PCI pooled analysis suggested that longer DAPT duration was beneficial for MACE reduction in complex but not in non-complex PCI patients, albeit prolonged DAPT resulted in greater bleeding irrespective of PCI complexity [4] . In addition, DAPT included clopidogrel in majority of the patients in this meta-analysis, rather than potent P2Y 12 therapy.
Interestingly, on propensity stratified analysis although we observed a benefit for lower 1- This may be due to 1) limited sample size to demonstrate interaction; 2) selection bias resulting in healthier patients receiving prasugrel, who may not be at highest risk, affirming the well-described risk-benefit paradox [35] ; 3) consideration of only high risk procedural characteristics in the study definition rather than high risk patient factors such as STEMI, diabetes or prior PCI where prasugrel may be most beneficial [13, 36, 37] ; 4) other mechanisms at play to increase platelet reactivity and ischemic risk in complex PCI patients with diabetes and CKD, which may not be attenuated by P2Y 12 inhibitors [38] ; 5) adherence to medications was not assessed and decreased compliance or cessation of prasugrel and switching to clopidogrel may have been a contributor to the observed outcomes. However, adherence at 90-days is expected to be ≥90%; sensitivity analysis excluding patients switching treatment prior to discharge observed similar outcomes in the main study [18] .
Limitations
PROMETHEUS was an observational study and prospectively collected data were retrospectively extracted and although validated at site level, were not centrally adjudicated. Information on cardiovascular and non-cardiovascular causes of death was not available. We considered a definition for complex PCI based on site reported standard high-risk angiographic/procedural characteristics, which were not validated by a core lab. However each component was associated with greater adjusted hazard for early and late MACE. SYNTAX scores were not available and could not be used to support our definition of complex PCI. Although certain variables used in other reported definitions of complex PCI were unavailable, our results confirm the internal validity of the study definition demonstrating significantly greater risk of early and late outcomes in complex PCI patients. The sample size for this subgroup analysis was limited and hence the findings for the role of prasugrel in complex PCI are merely exploratory. Comparisons between prasugrel and clopidogrel may be influenced by unmeasured confounders resulting in treatment selection bias. We did not have information on adherence to antiplatelet therapy through 1-year follow-up. Numbers are presented as n (%) unless indicated otherwise.
CONCLUSIONS
BMS, bare metal stent; DES, drug eluting stent; GPI, glycoprotein 2b3a inhibitor; LMWH, low molecular weight heparin;
